Add BrightSurf on Google Email

Perspectives on obesity management and the use of anti-obesity medicine

A new study found that both employed people with obesity and employer representatives acknowledge the impact of obesity on future health problems and perceive lifestyle change alongside anti-obesity medications as the most effective approach for maintaining weight-loss reduction. Cost of medication coverage remains a significant barrie...

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalPopulation Health Management·TypeSurvey·DateApr 9, 2025

Gold battles cancer

A French research team has discovered that an organogold(III) complex accumulates selectively in the mitochondria of lung cancer cells, demonstrating its potential as an anticancer treatment. The complex's antitumor activity is attributed to its interactions with specific biological molecules, disrupting their function.

SourceWiley·JournalAngewandte Chemie International Edition·TypeExperimental study·DateApr 2, 2025

Blood cancer patients taking Bruton Tyrosine Kinase inhibitors should continue treatment at the time of COVID-19 vaccination, study shows

A new study suggests that blood cancer patients receiving Bruton Tyrosine Kinase inhibitors should continue their therapy while getting vaccinated against COVID-19. The IMPROVE trial found no improvement in antibody responses when BTKi therapy was paused for three weeks around the time of vaccination.

SourceUniversity of Birmingham·JournalThe Lancet Haematology·TypeRandomized controlled/clinical trial·DateApr 1, 2025

Low-dose apixiban comparable to full dose for preventing VTE recurrence in patients with cancer

A new study has found that a lower dose of the blood-thinning medication apixaban is as effective as the full dose in preventing recurring blood clots in patients with active cancer. Patients who received the lower dose experienced fewer bleeding complications and similar VTE recurrence rates compared to those on the standard dose.

SourceAmerican College of Cardiology·JournalNew England Journal of Medicine·DateMar 29, 2025

Clinical characteristics, treatment effects and risk factors of liver cirrhosis in patients with Wilson’s disease hepatic type

A single-center retrospective study analyzed clinical data, imaging, histopathological manifestations, genetic testing results, and treatment effects in 48 WD patients. The study found age at diagnosis, K-F ring presence, and higher immunoglobulin G levels were associated with cirrhosis risk factors.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateMar 28, 2025

WIN Consortium leading the future of precision cancer medicine

The WIN Consortium is transforming cancer care through personalized medicine, leveraging AI, molecular profiling, and clinical trials. The organization's innovations, including N-of-1 clinical trials and WINTHER and WINGPO trials, are helping clinicians make more precise treatment decisions and improving outcomes for cancer patients.

SourceImpact Journals LLC·JournalOncotarget·TypeNews article·DateMar 18, 2025

Combination immunotherapy before surgery may increase survival in people with head and neck cancer

Researchers at University of North Carolina Health Care found that combination immunotherapy before surgery increased survival rates in people with head and neck squamous cell carcinomas. The treatment regimen doubled or tripled the response rate versus single immunotherapy, leading to a survival benefit for up to a third of patients.

SourceUniversity of North Carolina Health Care·JournalCancer Cell·TypeRandomized controlled/clinical trial·DateMar 13, 2025

Targeted alpha therapy: a breakthrough in treating refractory skin cancer

A team of researchers from Chiba University has developed a novel radioactive drug that targets and treats metastatic melanoma. The treatment utilizes astatine-211 labeled peptide analog, which shows high accumulation in tumors, rapid clearance from non-target organs, and significant tumor suppression.

SourceChiba University·JournalEuropean Journal of Nuclear Medicine and Molecular Imaging·TypeExperimental study·DateMar 12, 2025

Diabetes drug could help cancer patients make better recovery

A new study published in the European Journal of Preventive Cardiology found that a type of diabetes medication called SGLT2 inhibitors can significantly lower the risk of heart failure and hospital visits related to heart failure in cancer patients. The benefits were particularly promising for breast cancer patients receiving anthracy...

SourceUniversity of East Anglia·JournalEuropean Journal of Preventive Cardiology·TypeMeta-analysis·DateMar 5, 2025

Pusan National University researchers develop self-protecting nanoparticles for effective treatment of colorectal cancer

Researchers at Pusan National University have developed a novel drug delivery system that uses nanoparticles to target and kill colorectal cancer cells. The system, which involves encapsulating cancer cell-activated nanoconjugates in an alginate matrix, can selectively deliver drugs to tumor cells while minimizing side effects.

SourcePusan National University·JournalChemical Engineering Journal·TypeExperimental study·DateFeb 18, 2025

New computational tool could improve discovery of cancer treatments

A new tool named retriever extracts disease-specific drug response signatures to predict cancer treatment combinations, improving personalized treatment strategies. The tool refines predictions using single-cell RNA sequencing data and demonstrates its potential in identifying effective treatments for triple-negative breast cancer.

SourceeLife·JournaleLife·DateFeb 4, 2025

CNIC scientists design an effective treatment strategy to prevent heart injury caused by a class of anticancer drugs

Researchers at the CNIC have designed a treatment strategy to protect the heart against cardiotoxic effects of anthracyclines, a common class of anticancer drugs. Empagliflozin, an SGLT2 inhibitor, has been shown to preserve cardiac function and metabolism in experimental models.

SourceCentro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.)·JournalJACC CardioOncology·TypeExperimental study·DateFeb 4, 2025

NUS researchers pioneer DNA-tagged gold nanoparticles for targeted cancer treatment

The team's novel technique enables high-throughput screening of nanoparticle shapes, sizes, and modifications, reducing associated screening costs. The research demonstrates the distinct preferences of tumour cells for certain nanoparticle configurations, enabling personalized cancer treatments that are safer and more effective.

SourceNational University of Singapore·JournalAdvanced Functional Materials·TypeExperimental study·DateJan 27, 2025

Boosting this molecule could help retain muscle while losing fat

A new study from the Salk Institute has discovered that a protein called BCL6 plays a crucial role in maintaining healthy muscle mass. Increasing BCL6 levels successfully reversed muscle losses in mice, suggesting that pairing GLP-1 medications with a BCL6-boosting drug could help counteract unwanted muscle loss.

SourceSalk Institute·JournalProceedings of the National Academy of Sciences·DateJan 23, 2025

UTHealth Houston research: Children born to young men with cancer have slight increases in preterm birth, low-birth-weight children, but not birth defects

According to UTHealth Houston research, adolescent and young adult men with cancer have a slightly elevated risk of having preterm birth and children with low birth weight. However, the likelihood of live birth was highest for fathers who had thyroid cancer and lowest for those with gastrointestinal cancer.

SourceUniversity of Texas Health Science Center at Houston·JournalJNCI Journal of the National Cancer Institute·TypeData/statistical analysis·DateJan 16, 2025

Trastuzumab emtansine improves long-term survival in HER2 breast cancer

The phase 3 KATHERINE clinical trial found trastuzumab emtansine to be an effective adjuvant treatment for high-risk HER2-positive breast cancer patients, reducing the risk of death or invasive disease by 46% and improving survival. The study showed consistent benefits across patient subgroups, supporting T-DM1 as a new standard of care.

SourceUniversity of Pittsburgh·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateJan 15, 2025

What is metformin’s secret sauce?

A new Northwestern Medicine study reveals how metformin lowers glucose levels by targeting mitochondrial complex I in cells. The drug also improves COVID outcomes and reduces inflammation, suggesting that mitochondrial complex I inhibition may be a unifying mechanism behind its diverse effects.

SourceNorthwestern University·JournalScience Advances·DateDec 18, 2024

Opioids interfere with cancer immunotherapy but these drugs could help

New research from the University of Pittsburgh found that opioids can suppress the immune system and reduce the effectiveness of immunotherapy for head and neck cancer. However, peripherally restricted OPRM1 antagonists (PAMORAs) may block opioid-induced immunosuppression and improve response rates to immune checkpoint inhibitor therapy.

SourceUniversity of Pittsburgh·JournalJournal for ImmunoTherapy of Cancer·DateDec 5, 2024

Genetic data from ‘biobanks’ may help improve prediction of effectiveness, side effects of common medications, study finds

A new framework developed by UCLA researchers suggests that genetic data from large libraries of sequenced human genomes can improve the predictive power of genetics in determining how well a patient will respond to commonly prescribed medications and the severity of any side effects. The study, which analyzed data from over 342,000 pe...

Gluing treatment to cancer

Combining PVA with a boron-containing compound improved the effects of radiation therapy for cancer, making it more selective of tumor cells and prolonging drug retention. This breakthrough could lead to more effective treatment options for challenging cancers.

SourceUniversity of Tokyo·JournalJournal of Controlled Release·TypeExperimental study·DateDec 3, 2024